Valuation: Annexon, Inc.

Market Cap 690M 606M 572M 521M 976M 66.14B 983M 6.84B 2.65B 33.79B 2.59B 2.53B 109B P/E 2026 *
-3.51x
P/E 2027 * -3.72x
Enterprise Value 600M 526M 497M 453M 848M 57.46B 854M 5.95B 2.3B 29.36B 2.25B 2.2B 94.35B EV / Sales 2026 *
-
EV / Sales 2027 * 15.7x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day-4.21%
1 week-13.95%
Current month-26.32%
1 month-29.32%
3 months-29.32%
6 months-32.15%
Current year-27.49%
1 week 3.63
Extreme 3.63
4.36
1 month 3.63
Extreme 3.63
5.32
Current year 3.63
Extreme 3.63
7.18
1 year 2.54
Extreme 2.54
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
22.49
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 30/11/2014
Director of Finance/CFO 53 31/05/2019
Chief Tech/Sci/R&D Officer 68 26/07/2023
Director TitleAgeSince
Director/Board Member 58 30/11/2014
Director/Board Member 67 04/02/2021
Director/Board Member 56 31/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Director

175,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 613,497 0.3775%
11/05/26 Buy

Director

8,000 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-4.21%-13.95%+30.47%+46.18% 690M
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.87%-1.00%+35.37%+156.68% 27.59B
Weighted average by Cap. -0.77%+0.27%+36.30%+128.91%

Financials

2026 *2027 *
Net sales - 38.92M 34.15M 32.25M 29.39M 55.02M 3.73B 55.41M 386M 149M 1.91B 146M 143M 6.12B
Net income -212M -186M -175M -160M -299M -20.28B -301M -2.1B -813M -10.36B -795M -777M -33.31B -209M -184M -173M -158M -296M -20.06B -298M -2.08B -804M -10.25B -786M -769M -32.94B
Net Debt -90.55M -79.46M -75.04M -68.39M -128M -8.68B -129M -898M -348M -4.43B -340M -333M -14.25B -80.71M -70.82M -66.89M -60.95M -114M -7.74B -115M -800M -310M -3.95B -303M -296M -12.7B
Logo Annexon, Inc.
Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis.
Employees
92
Date Price Change Volume
25/09/26 US$3.640 -4.21% 3,511,268
24/09/26 US$3.800 -1.81% 2,022,863
23/09/26 US$3.870 -7.42% 2,423,554
22/09/26 US$4.180 -0.95% 2,000,238
21/09/26 US$4.220 -0.24% 4,187,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.640USD
Average target price
15.29USD
Spread / Average Target
+319.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock